STARPHARMA HOLDINGS

SPL
End-of-day quote. End-of-day quote  - 10/19
1.165AUD 0.00%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Other Pharmaceuticals
Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The Company is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The Company has two core development programs: VivaGel portfolio and Dendrimer Enhanced Product (DEP) drug delivery. VivaGel BV for bacterial vaginosis (BV) is a women’s health product. It is available for sale under the brand names Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand). DEP is a drug delivery platform, which provides demonstrated reproducible preclinical benefits across various internal and partnered DEP programs, including improved efficacy, safety, and survival. The Company has three internal DEP products includes DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These internal DEP Products are in clinical development. The Company develops several products internally and others via commercial partnerships.

Number of employees : 50 people.
Sales per Business
20202021
Dendrimers6.03100%1.80100%
AUD in Million
Sales per region
20202021
Australia6.03100%1.80100%
AUD in Million
Managers
Name Title
Jacinth K. Fairley Chief Executive Officer & Executive Director
Nigel J. Baade Chief Financial Officer & Secretary
Robert Bain Thomas Non-Executive Chairman
David J. Owen Vice President-Research
Zita Peach Independent Non-Executive Director
David John McIntyre Independent Non-Executive Director
Lynda Cheng Independent Non-Executive Director
Filippa Shub Director-Intellectual Property
Tony Eglezos Vice President-Business Development
Jeremy R. Paull Vice President-Development & Regulatory Affairs
Shareholders
Name Equities %
Allan Gray Australia Pty Ltd. 43,597,242 10.7%
Allianz Global Investors Asia Pacific Ltd. 36,910,063 9.09%
FIL Investment Advisors (UK) Ltd. 33,514,716 8.25%
M&G Investment Management Ltd. 31,889,780 7.85%
ICM Investment Management Ltd. 19,046,000 4.69%
FIL Investment Management (Hong Kong) Ltd. 13,575,123 3.34%
The Vanguard Group, Inc. 9,158,081 2.25%
Vanguard Investments Australia Ltd. 5,091,054 1.25%
T&N Argyrides Investments Pty Ltd. 4,970,000 1.22%
Mirrabooka Investments Ltd. (Investment Management) 4,067,044 1.00%
Company contact information
Starpharma Holdings Ltd.
4-6 Southampton Crescent
Abbotsford, Victoria (VIC) 3067

Phone : +61.3.8532.2700
Fax : +61.3.9510.5955
Web : http://www.starpharma.com
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
STARPHARMA HOLDINGS LIMITED-29.35%354
JOHNSON & JOHNSON4.12%431 385
ROCHE HOLDING AG15.84%337 562
NOVO NORDISK A/S57.04%239 813
PFIZER, INC.14.34%235 986
ELI LILLY AND COMPANY43.51%219 674
MERCK & CO., INC.-2.82%201 219
ABBVIE INC.0.28%189 883
ASTRAZENECA PLC19.32%186 853
NOVARTIS AG-8.32%186 067
BRISTOL-MYERS SQUIBB COMPANY-7.16%127 972
SANOFI4.99%120 688
AMGEN INC.-10.06%117 421
GLAXOSMITHKLINE PLC4.86%97 209
ALLERGAN PLC0.97%63 659
CHUGAI PHARMACEUTICAL CO., LTD.-27.60%57 347
BAYER AG-1.82%54 048
JIANGSU HENGRUI MEDICINE CO., LTD.-46.59%49 531
DAIICHI SANKYO COMPANY, LIMITED-21.57%46 522
TAKEDA PHARMACEUTICAL COMPANY LIMITED-14.91%43 985
ASTELLAS PHARMA INC.21.71%31 472
Brand Portfolio
» More brands of Starpharma Holdings Limited